Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

doi:10.1002/cam4.50

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Cancer medicine - 1 Feb 2013

Niessner Heike, Forschner Andrea, Klumpp Bernhard, Honegger Jürgen B, Witte Maria, Bornemann Antje, Dummer Reinhard, Adam Annemarie, Bauer Jürgen, Tabatabai Ghazaleh, Flaherty Keith, Sinnberg Tobias, Beck Daniela, Leiter Ulrike, Mauch Cornelia, Roesch Alexander, Weide Benjamin, Eigentler Thomas, Schadendorf Dirk, Garbe Claus, Kulms Dagmar, Quintanilla-Martinez Leticia, Meier Friedegund

Abstract excerpt

Brain metastases are the most common cause of death in patients with metastatic melanoma, and the RAF-MEK-ERK and PI3K-AKT signaling pathways are key players in melanoma progression and drug resistance. The BRAF inhibitor vemurafenib significantly improved overall survival. However, brain metastases still limit the effectiveness of this therapy. In a series of patients, we observed that treatment with vemurafenib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Culture Media, Conditioned

Share to GTP Phosphohydrolases

Share to Indoles

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 24133630
DOI: 10.1002/cam4.50
PMCID: PMC3797558

Genes

BRAF
PTEN
KIT
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.PMID 24133630Read ↗

PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.Semantic proximity Read ↗

BRAF-MEK inhibition in melanoma brain metastases: a new hope.Semantic proximity Read ↗

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Semantic proximity Read ↗

Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.Semantic proximity Read ↗

Melanoma brain metastases and vemurafenib: need for further investigation.Semantic proximity Read ↗

Targeting brain metastases in patients with melanoma.Semantic proximity Read ↗

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.Semantic proximity Read ↗

Acquired and intrinsic resistance to vemurafenib in BRAF <sup>V600E</sup> -driven melanoma brain metastasesSemantic proximity Read ↗

Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.Semantic proximity Read ↗

Melanoma brain metastasis: overview of current management and emerging targeted therapies.Semantic proximity Read ↗

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.Semantic proximity Read ↗

Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.